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Summary
Non-alcoholic fatty liver disease (NAFLD), the most common chronic liver disease
in the Western world, is tightly associated with obesity and metabolic syndrome.
NAFLD entails an increased cardiometabolic and liver-related risk, the latter
regarding almost exclusively non-alcoholic steatohepatitis (NASH), the progressive
form of NAFLD. Pathogenetic models encompass altered hepatic lipid partitioning
and adipokine action, increased oxidative stress, free fatty acid lipotoxicity. On this
basis, lifestyle-, drug- or surgically induced weight loss, insulin sensitizers, antioxi-
dants, lipid-lowering drugs have been evaluated in NAFLD/NASH. Most trials are
small, of short duration, nonrandomized, without histological end points, thus
limiting assessment of long-term safety and efficacy of proposed treatments.
All NAFLD patients should be evaluated for their metabolic, cardiovascular and
liver-related risk. Liver biopsy remains the gold standard for staging NAFLD, but
non-invasive methods are under intense development. Weight loss through lifestyle
intervention is the initial approach, because of established efficacy on NAFLD-
associated cardiometabolic abnormalities, and to emerging benefits on necroin-
flammation and overall disease activity in NASH. Bariatric surgery warrants
further evaluation before it can be routinely considered in morbidly obese NASH.
Larger- and longer-duration randomized trials assessing safety and benefits of
drugs on patient-oriented outcomes are needed before pharmacological treatment
can be routinely recommended for NASH.
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Introduction
Non-alcoholic fatty liver disease (NAFLD) is the most
common chronic liver disease in the Western world. We
will discuss the epidemiology of NAFLD, recent diagnostic
and pathogenetic acquisitions, the evidence for current
therapeutic approaches and unresolved issues. Online
medical databases and abstracts from National and
International meetings were searched for: non-alcoholic
steatohepatitis (NASH), NAFLD, non-alcoholic, fatty
liver, liver fat, steatosis, metabolic liver disease. Method-
ological quality of original human studies through July
2009 was scored according to Downs and Black checklist
independently and in duplicate by two authors (G. M., M.
C.): studies scoring >16 points (range 0–27) were analysed
to assess the natural history, pathogenesis, prognosis and
treatment of NAFLD (1). Meta-analyses following the
Guidelines for Meta-Analyses of Observational Studies in
Epidemiology and the Cochrane Handbook for systematic
Reviews of Interventions were also included (2).
Financial support/disclosure: this work was supported in part by grants
from the Piedmont Regional Funds Comitato Interministeriale per la
Programmazione Economica 2008.
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The flow of study selection is reported in Fig. S1
Definition
The NAFLD is defined by a hepatic fat infiltration >5%
hepatocytes, as essessed by liver biopsy (LB) or magnetic
resonance spectroscopy [MRS; sensitivity of 98% for ste-
atosis; (3)], in the absence of excessive alcohol intake,
defined by two standard drinks (20 g ethanol) daily for
men and one standard drink (10 g ethanol) daily for
women (4).
The NAFLD was traditionally categorized as ‘primary’
or ‘secondary’ depending on the underlying aetiology.
‘Primary’ NAFLD occurs most commonly, its pathogenesis
is unknown, is tightly associated with insulin-resistance
and metabolic syndrome, and will be the focus of this
review. Before formulating a diagnosis of primary NAFLD,
other competing aetiologies of hepatic steatosis (‘second-
ary’ NAFLD) with specific treatments and different
prognoses should be ruled out (Table 1). Currently, the
term ‘secondary’ NAFLD is discouraged and preferred
nomenclature includes the known causative factor and the
resultant pathology, e.g. total parenteral nutrition-induced,
drug-induced steatosis/steatohepatitis.
The NAFLD encompasses a histological spectrum
ranging from simple steatosis to non-alcoholic steatohepa-
titis (NASH), defined by steatosis, hepatocellular damage
and lobular inflammation (4). The distinction between
these two histological subtypes can currently be made
only by LB, and has prognostic significance, as NASH can
progress to cirrhosis (see below).
Epidemiology and natural history
Depending on the sensitivity of the method used to detect
hepatic steatosis, NAFLD has a prevalence in the general
western adult population of 30% by MRS (sensitivity of
98% for steatosis), of 14–26% by ultrasound (sensitivity
ranging 49–94%, insensitive for steatosis involving <30%
hepatocytes, (5) and of 6–12% by liver enzyme elevation
(6,7). Notably, serum transaminases can be normal in up to
75% of cases of NAFLD (3,4).
Beyond different case definitions, ethnicity and metabolic
factors affect disease prevalence. The prevalence of NAFLD
is 14–16% in Asians, 31–33% in African–Americans and
Caucasians and 45% among Hispanics, differences partly
explained by different visceral adiposity distribution (8).
Metabolic disorders increase the risk of NAFLD, occurring
in 65–70% of obese and diabetic and in up to 96% of
morbidly obese subjects(5,9). Another emerging associa-
tion is between NAFLD and obstructive sleep apnoea
syndrome (OSAS), which can be found in >50% of obese
patients with NAFLD (10,11).
Beside overall risk of NAFLD, metabolic factors impact
also the severity of liver disease: NASH affects 3% of the
general population, 20–30% of obese and diabetic and
35–40% of morbidly obese subjects (4,9). The presence of
OSAS, as well, increases by fourfold the risk of NASH in
morbidly obese patients, independently of overweight (12):
whether chronic intermittent hypoxia promotes liver injury
warrants further prospective investigation.
Overall, NAFLD is a slowly progressive disease, with
morbidity and mortality affecting a minority of patients.
(13–15). In the Third National Health and Nutrition
Examination Survey (NHANES-III), NAFLD had higher
overall (OR 1.038, 95% CI: 1.036–1.041, P < 0.0001) and
liver-related mortality (OR 9.32, 95% CI: 9.21–9.43,
P < 0.0001) than the general population over 8.7 years,
after adjusting for age, gender, race, body mass index
(BMI), hypertension and diabetes(7). Cardiovascular
disease (CVD), malignancy and liver disease were the
leading causes of death in NAFLD. Mortality was particu-
larly increased among the 45–54 age group, with a stan-
dardized mortality ratio of 4.40 (95% CI: 1.27–13.23) for
all-causes and of 8.15 (95% CI: 2.00–33.20) for CVD.
Further evidence connects NAFLD to cardiometabolic
complications:
1. Diabetes: in community- and population-based pro-
spective studies, NAFLD predicted incident diabetes
independently of traditional risk factors, including obesity,
insulin resistance, metabolic syndrome and C-reactive
protein (16–21).
Table 1 Types of non-alcoholic fatty liver disease (NAFLD)
Type Association
Primary Obesity, insulin resistance and metabolic
syndrome, diabetes, dyslipidemia
Secondary
Viral infection Hepatitis B, C, Epstein-Barr
Autoimmune or
hereditary diseases
Autoimmune hepatitis, systemic
erythematosus lupus*, Wilson disease,
hereditary hemochromatosis, alpha-1-
antitrypsin deficiency, celiac disease
Drugs Amiodarone, tamoxifen, corticosteroids,
corticosteroids, methotrexate, Calcium
channel blockers, valproate, highly
active antiretroviral therapy
Toxins Organic solvents, mushroom toxins
Endocrine-metabolic
conditions
Hypobetalipoproteinemia, lipodystrophy,
hypopituitarism, Weber-Christian
syndrome, Cushing syndrome, Reyes
syndrome, pregnancy, hypothyroidism
Nutritional Total parenteral nutrition, rapid weight
loss, starvation, jejuno-ileal bypass
*Low titer antinuclear antibodies (1 : 160) or anti-smooth muscle actin
antibodies 1 : 40 can be seen in up to 33% of patients with NAFLD.
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2. CVD: a meta-analysis of five community-based and
two hospital-based cross-sectional studies found an inde-
pendent association between NAFLD and subclinical
carotid atherosclerosis (OR: 3.13, 95% CI: 1.75–5.58,
P < 0.0002) (22); other cross-sectional and prospective
studies confirmed an independent association of NAFLD
with different cardiovascular outcomes, including systemic
and coronary endothelial dysfunction, myocardial dysfunc-
tion and clinical events (6,15,23–31).
Whereas cardiovascular risk seems increased in all patients
with NAFLD, without significant differences between
NASH and simple steatosis (32), the hepatological progno-
sis differs between histopathological subtypes (13,14):
while steatosis progresses to fibrosis in <5% of cases,
NASH develops progressive fibrosis in 30% of cases over
3–4 years and cirrhosis in 25% of cases over 8–10 years;
once cirrhosis develops, median survival approaches 6
years, with an overall mortality rate 1.5- to 1.75-fold
higher than steatosis (13–15,33). Consistently, most
patients with cryptogenic cirrhosis come from unrecog-
nized NASH, which lost the histological feature of hepatic
steatosis with disease progression (34).
Pathogenesis: the two-hit hypothesis revisited
According to the original ‘two-hit’ model, hepatic fat accu-
mulation is the first hit and is the pre-requisite for liver
injury to develop. The fatty liver subsequently becomes
vulnerable to ‘second hits’ leading to hepatocyte injury,
inflammation and fibrosis. This view has been challenged
by recent findings, suggesting the same noxae may deter-
mine both fat infiltration and necroinflammation/fibrosis,
and that hepatic triglyceride (TG) accumulation may actu-
ally protect hepatocytes from free fatty acid (FFA) toxicity.
Mechanisms underlying hepatic fat accumulation
The NAFLD develops when FFA uptake and synthesis
exceed oxidation and resecretion into the blood. Mecha-
nisms potentially contributing to hepatic steatosis include:
adipose tissue-derived and dietary FFA overflow to the
liver, hepatic de novo lipogenesis (DNL), impaired hepatic
FFA elimination through oxidation and secretion into very
low density lipoprotein triglycerides (VLDL-TG). Stable
isotope technique demonstrated that 59% of hepatic TG
derive from adipose tissue FFA spill-over, 26% from DNL
and 15% from dietary fat in NAFLD (35). DNL, as oppo-
site to healthy subjects, is constitutively elevated in NAFLD
and fails to suppress in the fasting state. Hepatic VLDL
secretion rates in NAFLD are inadequate to the increased
hepatic TG availability: while in healthy subjects VLDL-
TG secretion rate increases linearly with increasing intra-
hepatic TG disposal, in NAFLD it reached a plateau as
hepatic TG infiltration exceeded 10% (36). VLDL-TG syn-
thesis and secretion are more compromised in NASH than
in simple steatosis, thus further aggravating hepatic lipid
retention (37). Therefore, increased uptake of adipose
tissue-derived FFA, an inappropriately elevated DNL and
an inadequate export of TG from the liver are responsible
for hepatic steatosis in NAFLD.
Adipokines
Visceral adipose tissue is believed to play a pivotal role in
the pathogenesis of NAFLD and current therapeutic
approaches aim at reducing visceral adipocyte-derived
adipokine and FFA overflow to the liver by weight loss
and insulin-sensitizers. The role of single adipokines in the
pathogenesis of NAFLD and insulin resistance is described
in Table 2 and reviewed elsewhere (38). Most adipokines,
including tumor necrosis factor-a (TNF-a), resistin, angio-
tensin II, induce insulin resistance and low-grade inflam-
mation through activation of stress-related protein kinases,
i.e. c-Jun NH2-terminal kinase-1 (JNK-1), and of the
inhibitor kappa kinase beta (IKKb)/nuclear factor kappa B
(NF-kB) pathway. Activated JNK-1 phosphorylates insulin
receptor substrate-1 protein, thereby inactivating insulin
receptor signalling. IKKb activation leads to translocation
of the transcription factor NF-kB into the nucleus, resulting
in a feed-forward loop enhancing synthesis of proinflam-
matory cytokines, including IL-6, TNF-a, IL-1b and mono-
cyte chemoattrattant protein-1.The net result is a state of
hepatic and systemic low-grade chronic inflammation and
insulin resistance (39–41).
Leptin, TNF-a and IL-6 promote also hepatic fibrogen-
esis through hepatic stellate cells (HSC) activation, both
directly by binding to HSC receptors and indirectly through
transforming growth factor-b secretion by Kupffer cells
(38,42).
Consistently, TNF-a pathway antagonism reversed
hepatic insulin resistance and liver injury in ob/ob mice and
in human NASH (38,43).
Contrary to other adipokines, adiponectin protects
against the development of NAFLD, and hypoadi-
ponectinemia has been consistently linked with liver disease
in experimental and human NAFLD, even in the presence
of normal plasma levels of other adipokines, suggesting it
may be an early event in the pathogenesis of NAFLD (44).
Consistently, administrations of recombinant adiponectin
markedly improved NASH in ob/ob mice and the histologi-
cal improvement observed in NASH with thiazolidinedi-
ones (TZDs) correlate tightly with enhanced adiponectin
secretion and adipocyte insulin sensitivity than with vis-
ceral fat mass changes, suggesting functional impairment of
adipocyte is central to the pathogenesis of NASH (45,46).
Retinol binding protein 4 (RBP4) was identified in the
adipose tissue of mice rendered insulin resistant by adipose-
432 Non-alcoholic fatty liver disease G. Musso et al. obesity reviews
© 2009 The Authors
Journal compilation © 2009 International Association for the Study of Obesity. obesity reviews 11, 430–445
specific inactivation of the glucose transporter GLUT4
(47). Hepatic, adipose tissue and plasma levels of RBP4
correlate with the degree of obesity, insulin resistance
and liver fat content (48,49). Mechanisms whereby RBP4
interferes with insulin action are incompletely understood,
but may involve hepatic retinol metabolism (50).
FFA lipotoxicity
An emerging concept is that hepatic TG accumulation is
not per se toxic, but rather would protect the hepatocyte by
buffering the accumulation of toxic FFA: inhibiting hepatic
TG synthesis improved hepatic steatosis, but exacerbated
liver injury, necroinflammation and fibrosis in obese mice
with NASH (51). In this model, the severity of liver injury
paralleled the extent of hepatic FFA accumulation, of cyto-
chrome P450 2E1 activation and of lipid peroxidation.
Conversely, in humans hepatic FFA uptake inhibition with
acipimox acutely improved hepatic injury and insulin
sensitivity, without affecting liver TG stores (52). FFA
lipotoxicity involves the following mechanisms:
1. JNK-1-mediated hepatocyte apoptosis activation
(53). Despite a similar ability to cause steatosis, saturated
(SFA) seem substantially more cytotoxic than unsaturated
Table 2 An overview of main mechanisms involved in the pathogenesis of NAFLD
Membrane fatty acid transporters involved in NAFLD
Activators Inhibitors Action Clinical implications
FATP5 Enhances facilitated hepatic FFA uptake Experimental FATP5 inhibition reverses
NAFLD
FABP4, FABP5 Enhances facilitated hepatocyte and
adipocyte FFA uptake
FAT/CD36 Enhances facilitated hepatic FFA uptake
Nuclear receptors involved in NAFLD
Activators Inhibitors Action Clinical implications
PPAR-a
(Present in
hepatocytes, muscle
and heart miocytes)
PUFA, fibrates,
eicosanoids,
adiponectin
Increases FAT/CD36-mediated FFA
uptake
Increases mitochondrial and peroxisomal
b-oxidation
Inhibits NF-kB pathway
Mediates PUFA and fibrate beneficial
effects on human and murine NAFLD
PPAR-g
(Present in
adipocytes,
hepatocytes and
hepatic stellate cells,
macrophages,
pancreatic b-cells,
endothelium)
TZD Enhances insulin action, FFA oxidation,
adiponectin secretion, hepatocyte FFA
uptake by FAT/CD36
Inhibits macrophage and hepatic stellate
cell activation
Inhibits secretion of proinflammatory
cytokines by adipocytes and
macrophages
TZD improve NAFLD in animals and
humans
SREBP-1c
(present in adipocytes
and hepatocytes)
Insulin,
endocannabinoids
(CB-1 agonists,
LXR-a, SOCS-3,
Homocystein,
endoplasmic
reticulum stress
SFA, TFA
Leptin, glucagon,
PUFA, AMPK
Enhances transcription of lipogenic
enzymes ACC, FAS, SCD-1
PUFA and metformin inhibit lipogenesis
LXR-a Oxysterols,
glucose
Enhances transcription of lipogenic
enzymes ACC, FAS, SCD-1;
Activates (SREBP)-1c transcription;
enhances FAT/CD36-mediated FFA
uptake
Exogenous antagonist 22-S-HC inhibits
lipogenesis in human muscle cells
(162,163).
ChREBP Glucose, LXR-a Enhances transcription of lipogenic
enzymes ACC, FAS
ChREBP deletion improved steatosis,
hyperlipidemia, hepatic and muscle
insulin resistance (164)
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Table 2 Continued
Adipokines involved in NAFLD
Activators Inhibitors Action Clinical implications
Leptin Overfeeding,
obesity,
glucocorticoids,
glucose, insulin
Fasting, sustained
exercise, cold
exposure, weight
loss
Central anorexigenic, insulin sensitizer,
increasing mitochondrial FFA oxidation
by malonyl-CoA synthesis inhibition,
stimulates AMPK, which activates ATP-
producing catabolic pathways, such as
b-oxidation, glycolysis and inhibits ATP-
consuming anabolic pathways; fibrogenic
action by hepatic stellate cell activation
Obese NAFLD patients, are leptin
resistant and have elevated leptin
levels. Leptin administration reduces
body mass index, hepatic fat content
and histological steatohepatitis in
lipoatrophic patients
TNFa Induces insulin resistance by reducing
GLUT-4 expression and LPL activity in
adipocytes and hepatocytes; induces
inflammation in the liver by activating
stress-related kinase JNK-1 and NF-kB
pathway
Experimental NAFLD is significantly
improved by hepatic TNF-a
antagonism
Pentoxifylline, a weak TNF-a inhibitor,
is currently tested in human NASH
Resistin TNF-a, IL-6, IL-1,
lipopolysacharride
Promotes insulin resistance by AMPK
activation and down-regulation of GLUT-4
in adipocytes;
Induces nuclear translocation of NF-kB
and TNF-a secretion from macrophages;
Resistin levels are increased in NAFLD
patients and correlate with histological
severity and with impaired hepatic
glucose metabolism
Resistin expression is markedly
reduced by thiazolidinediones, and
anti-resistin antibodies improve blood
glucose and insulin action in mice
with diet-induced obesity
Adiponectin Weight loss TNF-a, IL-6,
resistin, insulin,
glucocorticoids
It stimulates mitochondrial b-oxidation by
activating AMPK and inhibits lipogenesis
by down-regulating SREBP-1c; hepatic
anti- inflammatory/fibrogenic properties
by antagonizing TNF-a action and induc-
ing hepatic stellate cells apoptosis.
Recombinant adiponectin markedly
improves experimental NASH. It
mediates TZDs action on liver
histology in human NASH
Retinol binding
protein 4
Impairs insulin-stimulated glucose uptake
in muscles, enhances hepatic glucose
production and interferes with insulin
signalling in adipocytes, although the
mechanism is not fully clear. RBP4
correlates with hepatic steatosis
independently of obesity and insulin
resistance in chronic hepatitis C,
suggesting other mechanisms may link
RBP4 to steatosis, possibly hepatic
retinol metabolism
SOCS-3 TNF-a, IL-6 and
leptin
Adiponectin Enhances de novo lipogenesis by
up-regulating hepatic SREBP-1c;
Promotes insulin resistance by
phosphorylation of insulin receptor
substrate-2 (165)
Interleukin-6 SFA Inhibits adiponectin secretion and
lipoprotein lipase;
Stimulates SOCS-3 secretion;
Hepatic proinflammatory activity by
Kupffer cell activation.
Anti-IL-6 monoclonal antibody
(tocilizumab) proved beneficial in
other models of human pathology
and warrant investigation in NASH
(166)
22-S-HC, 22-S-hydroxycholesterol; ACC, acetyl CoA carboxylase; AMPK, AMP-activated protein kinase; ChREBP, carbohydrate response element
binding protein; FABP, fatty acid binding protein; FAS, fatty acid synthase; FAT, fatty acid traslocase; FATP, fatty acid transport protein; FFA, free fatty
acid; IL, interleukin; LPL, lipoprotein lipase; LXR-a, liver X receptor-a; NAFLD, non-alcoholic fatty liver disease; NF-kB, nuclear factor kappa B; NASH,
non-alcoholic steatohepatitis; PPAR, peroxisome proliferator-activated receptors; SCD, stearoyl-CoA desaturase; SFA, saturated fatty acids; PUFA,
polyunsaturated fatty acid; SOCS-3, suppressor of cytokine signalling-3; SREBP, sterol-regulatory element-binding protein; TFA, trans-fatty acids;
TNFa, tumor necrosis factor-a; TZD, thiazolidinediones.
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fatty acids; consistently, the liver of subjects with NASH is
characterized by a relative depletion of unsaturated FFA
in favour of SFA. Whether this is a consequence of the
peroxidative process or may have a pathogenetic role in
NASH warrants investigation (54).
2. Adipokine-independent hepatocyte IKKb-mediated
NF-kB pathway activation (55). Consistently, IKK inhibi-
tion reversed experimental NASH (56); NF-kB pathway
inhibition by salsalate improved glycemia and inflamma-
tory markers in obese humans, but the effects of this
approach on human NAFLD are unknown (57). Whether
the inhibition of the final effector of most proinflammatory
stimuli, i.e. NF-kB, is more effective and safer than a strat-
egy antagonizing selective adipokine pathways, needs
careful evaluation in future studies.
3. The SFA promote endoplasmic reticulum stress or
UPR (Unfolded Protein Response), a stress response to
various stimuli which is dys-regulated in NAFLD, and that,
when persistently activated, triggers hepatocyte apoptosis,
a critical step in the progression from simple steatosis to
NASH and cirrhosis (58–60). Apoptotic hepatocytes are
phagocytized by adiacent macrophages, eventually leading
to hepatic stellate cell activation and fibrogenesis. The role
of apoptosis in the progression of liver injury has been
highlighted in a recent proof-of-concept study, where
caspase inhibition improved hepatic fibrosis in an animal
model of NASH (61).
The relevance of FFA in the pathogenesis of liver injury
prompted research on mechanisms regulating FFA entry
and partitioning in hepatocyte. A total of 90% of the
hepatic uptake of circulating long-chain FA is mediated by
three saturable transmembrane carrier families: fatty acid
transport proteins (FATPs, six isoforms with different tissue
distribution), fatty acid translocase (FAT/CD36) and fatty
acid binding proteins (FABPs, nine different isoforms) (60).
The most extensively studied isoforms in NAFLD are
FATP5, FAT/CD36, FABP-1, FABP-4 and FABP-5: their
overexpression promotes steatosis, insulin resistance and
dyslipidemia in mice fed a high-fat diet, while their func-
tional deletion ameliorated these disorders (60,62,63). The
extension of these findings to human NAFLD is complex:
dietary and hormonal regulation of these proteins, the
phenotype deriving from the interaction among different
transmembrane carriers and the functional significance of
genetic variants are largely unknown (64–66).
Once in hepatocyte, SFA are unsaturated to monoun-
saturated fatty acids by stearoyl-coenzyme A (CoA)
desaturase-1 and subsequently esterified to TG by acyl
CoA:Diacylglycerol acyltransferase 1: while a high activity
of these enzymes is associated with higher hepatic TG
content in animal and human NAFLD, a reduced activity
promotes accumulation of intermediate SFA and dia-
cylglicerol that trigger hepatocyte apoptosis and insulin
resistance (67–69). If confirmed, the protective role of these
lipid partitioning enzymes in the prevention of liver injury
may have relevant therapeutic implications.
The other type of FFA that has been linked to the patho-
genesis of NAFLD are trans fatty acids, a form of unsatur-
ated fats relatively rare in nature, deriving mostly from
partial hydrogenation of vegetable oils, that can be found
in fast food and other processed foods. Compared with an
isocaloric high-fat diet, trans fat feeding resulted in higher
hepatic insulin resistance and necroinflammation and
enhanced hepatic interleukin-1b and TNF-a gene expres-
sion (70–73).
Nuclear transcription factors
Another growing research field involves the modulation of
hepatocyte glucose and lipid metabolism by nuclear tran-
scription factors, a superfamily of nuclear receptors that
upon ligand binding interact with DNA response elements
and co-ordinately regulate transcription of genes involved
in multiple metabolic and inflammatory pathways, at
hepatic and extrahepatic level. The nuclear transcription
factors linked to NAFLD (60) are reported in Table 2.
Role of genetics in NAFLD
The pathogenesis of NAFLD appears multifactorial,
involving both genetic and envirommental factors. Two
recent cohort studies and one community-based study in
different ethnicities estimated the heritability of NAFLD to
approach 35–40% of the total predisposition, even after
adjusting for age, gender, race and BMI (74–76). Several
genes modulating crucial steps of hepatic glucose and lipid
metabolism, inflammation and fibrogenesis, that have been
addressed in the pathogenesis section, have been candi-
dated by small cohort studies and are reviewed elsewhere
(77). Recently, two independent genome-wide association
population-based studies and three smaller cohort studies
found the missense variant rs738409 (encoding I148M) in
the Patatin-like Phospholipase 3 (PNPLA3) gene encoding
adiponutrin is associated with hepatic steatosis across dif-
ferent ethnic groups and independently of obesity and
diabetes status (78–82). Adiponutrin is a transmembrane
protein with phospholipase, TG lipase and acylglycerol
transacylase activity (transfers fatty acids to mono- and
di-acylglycerol), expressed in liver and adipocytes, whose
biological significance is largely unknown, that is induced
during adipocyte differentiation and in response to fasting
and peroxisome proliferator-activated receptor-g (PPAR-g)
activation and is down-regulated by insulin and TNF-a
(83).
Future confirmatory studies are needed to elucidate the
physiopathological mechanism(s) underlying this and other
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genetic associations before they can be used to predict
individual risk of steatosis, steatohepatitis and fibrosis and
to develop genetic molecular therapeutic strategies
Diagnostic issues
Diagnosing non-alcoholic
The threshold for defining significant alcohol consumption
has been recently debated, as obese and diabetic individuals
may develop steatosis with 1 daily alcohol drink and,
conversely, modest alcohol consumption may protect
against NAFLD (84,85). When history is unreliable or in
subjects with associated metabolic risk factors, it is hard to
differentiate alcoholic and non-alcoholic fatty liver. Con-
ventional variables, including mean corpuscular volume
(MCV), gammaglutamyltransferase and aspartate/alanine
aminotransferase (AST/ALT) ratio are inaccurate. Serum
carbohydrate-deficient transferrin has 81% sensitivity with
98% specificity in detecting chronic alcohol abuse (86), but
is not routinely measurable. The recently developed ‘ALD/
NAFLD Index’ (ANI) combines 6 readily accessible param-
eters (MCV, AST, ALT, height, weight and gender) into a
score (87): an ANI score >0 favours alcoholic liver disease
(ALD) whereas a value <0 predicts NAFLD with sensitivity
and specificity of 87.8% and 97.4%, respectively. As most
alcoholic patients in this cohort had high model for end-
stage liver disease scores, ANI score is likely to be more
applicable to patients with advanced liver disease and cir-
rhosis, while its accuracy for ambulatory patients remains
to be determined.
Diagnosing steatosis
As previously discussed, the diagnostic accuracy of liver
enzymes and ultrasonography for steatosis is suboptimal
and computed tomography (CT) and magnetic nuclear
resonance imaging (MNR) imaging are not routinely fea-
sible. Using multivariate regression analysis Kotronen et al.
developed and validated in 470 subjects the NAFLD liver
fat score, which combines five readily available variables
into a score to give the probability of increased liver fat as
assessed by MRS (Table S1) (82). The same authors also
developed an equation for estimating individual liver fat
content. Although promising, this score need independent
validation in different populations.
Assessing liver disease severity
As different histological subtypes of NAFLD have radi-
cally different prognoses, it is mandatory to identify
patients with progressive liver disease, who are at risk of
poor outcome (13–15). LB, currently the gold standard to
stage NAFLD, is not feasible in all NAFLD patients, is
costly, risky (procedural mortality 0.01%), invasive, and
suffers from sampling and intra- and inter-observer
variability [k coefficient of agreement of 0.55 for diagno-
sis of NASH and 0.69 for fibrosis staging, (88)]. There-
fore, non-invasive radiological and biochemical methods
for assessment of the severity of liver disease are under
development. Transient elastography, measuring liver
stiffness as an index of hepatic fibrosis, has limited accu-
racy in the presence of steatosis and obesity (89); MR
elastography is still investigational and hardly accessible.
Scoring systems combine clinical and biochemical param-
eters to individuate two histological features within
NAFLD: NASH and advanced fibrosis (Table S2). Identi-
fying advanced fibrosis would allow screening for com-
plications of liver disease (hepatocellular carcinoma,
oesophageal varices), while detecting NASH would allow
earlier treatment of a progressive disease. As treatments
with differential efficacy on necroinflammation and fibro-
sis will become available, both histological features will
have to be identified.
All these scores need independent and prospective vali-
dation in large, ethnically different cohorts before they can
replace LB to stage NAFLD and to monitor disease pro-
gression and response to treatment (90,91). The usual
experts recommendation of referring patients with clinical
risk factors for advanced liver disease (age  45 years,
obesity, diabetes, hypertriglyceridemia, metabolic syn-
drome) to gastroenterologists for LB is hardly feasible,
implying that 66% of obese subjects should get a gastro-
enterological evaluation. These figures highlights the inad-
equacy of current screening tools and the urgent need for
adequate, cost-effective and easy-to-use methods to screen
obese NAFLD patients for progressive liver disease.
Treatment
Histological evaluation of proposed treatment is essential,
as liver enzymes and steatosis spontaneously fluctuate over
time and often improve as necroinflammation and fibrosis
progress. Unfortunatey, few well-designed randomized
controlled trials (RCTs) with histological end points are
available.
Weight reduction through lifestyle modifications or
drugs (Table S3)
Because most NAFLD patients are overall or abdominally
obesity, weight reduction has been advised on the basis of
the benefits on multiple cardiometabolic risk factors. This
recommendation has long relied on small nonrandomized
trials, few with post-treatment histology, all of short dura-
tion (3–12 months), showing a weight loss of 4–23% was
safe, improved biochemical and histological NAFLD/
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NASH to a different extent, with improvement in necroin-
flammation and fibrosis being associated with higher
weight losses (92–100).
These concepts were confirmed in several well-designed
RCTs targeting weight loss through lifestyle interventions
similar to the Look AHEAD programme or drugs like
orlistat (101–105). In these RCTS, a weight loss 7% was
safe and achieved significant improvement in hepatic
steatosis, necroinflammation and NAS (NAFLD activity
score, a composite of steatosis and necroinflammation indi-
cating overall disease activity). Categorizing the patients
according the degree of weight loss, a weight loss 5%
improved steatosis insulin sensitivity and associated car-
diometabolic risk factors, but only a weight loss 7%
improved necroinflammation and NAS (97,101). Orlistat
was safe and well-tolerated with minor adverse gastrointes-
tinal complaints not requiring discontinuation of therapy.
On the basis of cross-sectional evidence for a protective
role of regular exercise against NAFLD, at least partly
through abdominal fat reduction (106–108), three RCTs
assessed the effects of physical activity alone on NAFLD:
beyond the known benefits on metabolic abnormalities,
1–6 months of regular moderate-intensity aerobic exercise
dose-dependently improved biochemical and MRS-
detected hepatic steatosis, even in the absence of body-
weight reduction, independently of changes in total or
visceral fat mass (109–111).
These preliminary data suggest aerobic exercise may
reduce hepatic steatosis, possibly through hepatic AMPK
activation (60), and should be strongly promoted for the
management of NAFLD, the benefits of which are not
exclusively contingent upon weight loss.
The effects of different doses of aerobic exercise on
NAFLD are being assessed by the trial ClinicalTrials.gov
identifier NCT00771108.
The optimal nutrient composition of the diet for NAFLD
is unknown: in the absence of prospective head-to-head
comparisons with histological assessment, some indications
can de drawn from available data (Table S4).
In summary, RCTs with post-treatment histology suggest
weight loss improves liver disease and associated metabolic
abnormalities in NAFLD. Importantly, while a 5% weight
loss improves steatosis and NAFLD-associated cardiometa-
bolic risk factors, recent RCTs suggest a >7% weight loss
would be required to improve necroinflammationa and
overall disease activity in NASH. The issue of a higher
threshold of weight loss necessary to improve the progres-
sive histological features of NASH needs further investiga-
tion. Long-term compliance is also a concern: even within
short-term trials, adherence to prescribed regimen did not
exceed 40% of patients, which raises doubts about the
durability of these benefits. This is even more concerning
since longer duration of these interventions may be
required to reverse hepatic fibrosis.
Bariatric surgery
NAFLD, as a component of the metabolic syndrome, rec-
ognizes ectopic fat accumulation as a key pathogenetic
event and is likely to benefit from surgery. The first bariat-
ric procedure, the jejuno-ileal bypass, worsened liver
disease because of severe malabsorption and bacterial over-
growth, and was replaced by Roux-en-Y gastric bypass,
laparoscopic adjustable banding, vertically banded gastro-
plasty and biliopancreatic diversion. The efficacy and safety
of these techniques on NAFLD has been recently reviewed
(9). Steatosis improved or resolved in 91.6% of cases,
steatohepatitis in 81.3%, fibrosis in 65.5%. NASH com-
pletely resolved in 69.5% of cases. Nevertheless, most
available studies were observational or retrospective, some
showing limited or no improvement in moderate-to-
advanced fibrosis (112); a recent 5-year prospective study
on morbidly obese subjects without advanced liver disease
showed a significant worsening of mild fibrosis 5 years after
surgery (113). Therefore, although promising, long-term
effects of surgery need to be evaluated in homogeneous
well-designed multi-center trials.
Insulin sensitizers: metformin and TZDs (Table S3)
Metformin improves insulin resistance by decreasing
hepatic glucose production and increasing skeletal muscle
glucose uptake. It also reduces hepatic expression of
TNF-a, a mediator of hepatic insulin resistance and necro-
inflammation, increases FFA oxidation and suppress lipo-
genesis through AMP kinase activation (38). Following few
fairly encouraging small uncontrolled trials (114,115),
safety and efficacy of metformin in NAFLD was evaluated
in four RCTs (two with post-treatment histology). (116–
119). Overall, metformin was safe and well-tolerated in
these studies, with no cases of lactic acidosis and gas-
trointestinal intolerance as the most common side effect,
not generally requiring discontinuation of therapy. Despite
its weight-losing properties (4–7% of initial body weight),
metabolic benefits and a significant improvement in tran-
saminases (112), metformin did not significantly improve
ultrasonographic NAFLD (113) or histological steatosis,
necroinflammation, NAS or fibrosis.(114,115).
The TZDs are agonists of the PPAR-g. After withdrawal
of troglitazone for hepatic toxicity, the second generation
TZD pioglitazone and rosiglitazone significantly improved
steatosis, necroinflammation and fibrosis in two uncon-
trolled trials, with 54% of patients not meeting histologic
criteria for NASH after 48 weeks (120,121).
Subsequently, three RCTs evaluated pioglitazone and
one RCT assessed rosiglitazone in NASH. Pioglitazone
significantly improved steatosis and necroinflammation;
fibrosis score also improved in one RCT (122–124).
Rosiglitazone significantly improved steatosis, but not
other histological features, although there was a significant
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delay in progression of necroinflammation and fibrosis in
the rosiglitazone arm (125).
Tiikkainen randomized drug-naive diabetic subjects to
rosiglitazone or metformin for 16 weeks (126): body
weight decreased with metformin but not with rosiglita-
zone. Despite similar improvements in HbA1c, insulin,
serum FFA and hepatic insulin sensitivity, steatosis and
ALT levels decreased (by 51% and by 31%, respectively)
only with rosiglitazone, closely correlating with the 123%
serum adiponectin increase.
In summary, TZDs showed significant benefits on
metabolic profile, steatosis and necroinflammation, while
the effects on liver fibrosis are inconsistent, possibly to
the short trial duration. NASH and associated metabolic
abnormalities relapse 1 year after discontinuation of TZDs,
suggesting long-term treatment may be required (127). This
issue raises major safety concerns related to weight gain,
bone loss in postmenopausal women and elderly diabetics
and to an apparently increased risk of cardiovascular
events. Finally, the efficacy of TZD in diabetic subjects
warrants further assessment, as most RCT enrolled non-
diabetic subjects and diabetes predicted lack of histological
response in one RCT (121). Further larger and longer dura-
tion RCTs enrolling diabetic subjects are warranted.
Lipid-lowering drugs
Atherogenic dyslipidemia is often associated with NAFLD
as part of the metabolic syndrome. Therefore, the potential
therapeutic role of lipid-lowering drugs in NAFLD has
been explored. A controlled trial with the fibrate gemfi-
brozil 600 mg daily for 4 weeks showed some biochemical
improvement in NAFLD, while clofibrate produced no
biochemical or histological improvement (128,129). Pro-
bucol, a lipid-lowering agent with strong antioxidant pro-
perties, improved liver enzymes in NASH in a small RCT
(130).
In uncontrolled trials HMG-CoA reductase inhibitors
pravastatin and atorvastatin were safe, improved serum
aminotransferases in NAFLD and showed also beneficial
effects on necroinflammation in two studies (131–134).
A recent RCT randomized 186 hyperlipidemic NAFLD
patients to atorvastatin, fenofibrate, or both (135). All
arms received lifestyle intervention. After 1 year, weight
loss in all arms averaged 11–13%, but biochemical plus
ultrasonographic regression of NAFLD was significantly
higher with atorvastatin alone or in combination, than
with fenofibrate. A weight loss >4% and concomitant use
of orlistat or metformin independently predicted response
to treatment. In another small placebo-controlled RCT, 1
year of simvastatin was safe but did not improve any his-
tological feature in NASH (136).
An important issue regarding the use of statins
in-patients with NAFLD is their potential hepatotoxicity.
After analysing available evidence, a consensus panel stated
concluded that patients with NAFLD are not at signifi-
cantly increased risk of severe hepatic toxicity with stan-
dard doses of statins and these drugs can be safely used
in-patients with NAFLD (137).
w-3 polyunsaturated fatty acid (PUFA) supplementation
improved biochemical and ultrasonographic steatosis in
several uncontrolled trials (138–140). In two RCTs, evalu-
ating PUFA plus diet vs. diet alone, PUFA significantly
improved liver enzymes and ultrasonographic steatosis was
reversed in an average of 23% patients. However, weight
loss was nearly double in the treatment arm compared with
controls in one RCT and was not reported in the other
RCT, making difficult to assess the role of PUFA in the
observed improvements (141,142). Safety and efficacy of
PUFA in NAFLD are being evaluated in RCT ClinicalTri-
als.gov NCT00845845, NCT00323414, NCT00819338,
NCT00760513, NCT00681408, NCT00230113.
Antioxidants and ursodeoxycholic acid (UDCA)
Because oxidative stress is believed to be the second hit
leading to inflammation in NASH, antioxidant vitamins E
and C have been evaluated in animal and human models,
yelding controversial results. An analysis on an intention-
to-treat basis of six RCTs concluded that despite the sig-
nificant improvements in liver enzymes and minor adverse
events, radiological and histological data are too limited to
support or repudiate the use of antioxidants in-patients
with NAFLD (143). In a 24-month RCT, the combination
of vitamin E and UDCA for 24 months significantly
improved steatosis, but not other histological features,
compared with either agent alone, in NASH (144).
The UDCA exerts its effect by reducing the portion of
hydrophobic bile acids contributing to oxidative stress.
Several clinical trials, of which only one assessed histology
and had a low-bias risk, have been conducted in NAFLD
(145). No significant differences in the degree of steatosis,
inflammation or fibrosis could be found between the
treated and placebo arms. Because of the heterogeneity
with respect to inclusion criteria, sample size, duration of
treatment and outcome, the Cochrane analysis concludes
that the data are insufficient to use UDCA in treatment of
patients with NAFLD (146).
Endocannabinoid receptor antagonists
Rimonabant antagonizes cannabinoid type 1 (CB1) recep-
tors in the central nervous system and the liver, reducing
food consumption and caloric intake and inhibiting hepatic
DNL and stellate cell activation (60).
In a subgroup of abdominally obese dyslipidemic
patients from the An International Study of Rimonabant
in Dyslipidemia With AtheroGenic Risk In Abdominally
Obese Patients (ADAGIO)-Lipids trial, rimonabant signifi-
cantly improved hepatic steatosis and all cardiometabolic
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risk factors compared with placebo (147). Patients with a
history of depression were excluded from the trial. Adverse
effects leading to discontinuation of the drug included gas-
trointestinal, depressive (2.0% vs. 1.3% of placebo) and
anxiety disorders (2.2% vs. 1.0%). Concern about the risk
of suicide associated with depressive and anxiety disorders
led food and drug administration (FDA) to deny approval
of rimonabant in the USA.
Angiotensin II type 1 receptor blockers
Preclinical studies demonstrated a marked decrease in
hepatic, insulin resistance, steatosis and fibrosis and stellate
cell activation with angiotensin II type 1 receptor blockers
(ARBs). Telmisartan and irbesartan possess also PPAR-g
agonism activity, thus improving insulin sensitivity experi-
mentally (148,149).
In humans, angiotensin II type 1 receptor polymorphisms
have been associated with the presence and severity of
NAFLD (150).These findings and the frequent coexistence
of hypertension with NAFLD prompted evaluation of
ARBs in NAFLD.
Following the encouraging results of two uncontrolled
trials with losartan (151,152), 54 hypertensive patients
with NASH were randomized to telmisartan or valsartan
(153). After 20 months, both agents improved blood
pressure and steatosis to a similar extent, but telmisartan
improved plasma lipids, insulin sensitivity, steatosis, necro-
inflammation and fibrosis more consistently than valsartan.
Larger- and longer-duration RCTs will assess the role of
ARB with PPAR-g activity in the treatment of NASH.
Other agents
Given the role of TNF-a in necroinflammation and
insulin resistance, anti-TNF therapy may be effective in the
treatment of NASH. Pentoxifylline, a TNF-a inhibitor,
significantly improved liver enzymes and insulin resistance
in uncontrolled trials (154) and consistently reduced
histological steatosis and necroinflammation in NASH
in a recent RCT (43).
NASH is associated with small intestinal bacterial over-
growth and increased gut permeability (155). Bacterial
endotoxins can stimulate hepatic inflammatory cytokine
production and increase oxidative stress leading to liver
injury. Probiotics improved aminotransferases and markers
of lipid peroxidation in human NAFLD (156) and are
being evaluated in ClinicalTrials.gov NCT00099723,
NCT00808990, NCT00870012.
Incretin glucagon-like protein1 (GLP-1) analogues
improve insulin secretion by stimulating pancreatic b-cell
growth and insulin release. This agents improved hepatic
steatosis and insulin resistance in ob/ob mice (157).
Exenatide, a GLP-1 analogue, significantly improved tran-
saminases in three RCTs enrolling diabetic subjects (158),
and its effect on liver histology in NASH are being tested in
ClinicalTrials.gov NCT00529204 and NCT00650546.
Liver transplantation
Indications for liver transplantation in NASH-related cir-
rhosis are the same as other aetiologies. Compared with
the latter, patients with NASH showed a trend for higher
1-year mortality, especially if having age 60 years,
obesity, diabetes or hypertension (159). NASH recurs in
50% of patients within 4 years, depending on higher
insulin resistance or steroid use, post-transplantation
weight gain, diabetes, highlighting the importance of con-
trolling metabolic risk factors to reduce disease relapse
(160).
Concluding remarks
Future research should clarify cellular and molecular
mechanisms regulating hepatocyte lipid partitioning and
metabolism and underlying altered hepatic insulin action
and lipoprotein metabolism and the increased low-grade
inflammation/oxidative stress. Delucidating such mecha-
nisms would provide the basis for understanding the pro-
gression from steatosis to NASH and the increased
cardiometabolic risk of NAFLD.
Currently, a diagnosis of NAFLD should prompt a thor-
ough metabolic and cardiovascular risk assessment to
correct associated cardiometabolic risk factors, but there is
no evidence that improving NAFLD would benefit car-
diometabolic and liver-related morbidity and mortality in
the long term.
There is also urgent need for effective and easy-to-use
non-invasive methods to assess the severity of liver disease
in NAFLD: while simple steatosis has a benign hepatologi-
cal prognosis and may be managed with measures aiming
at reducing cardiometabolic risk, NASH may progress to
end-stage liver disease and requires early hepatological
referral for experimental treatment and tight follow-up.
Despite the large number of drugs used to treat NASH,
most studies are small-sized and of short duration without
post-treatment histology. Therefore, there is no currently
established treatment for NASH. Lifestyle intervention
should be first-line treatment for all NAFLD patients: a
5% weight loss benefits steatosis and associated cardi-
ometabolic risk factors, while more consistent weight loss
may also improve necroinflammation and overall disease
activity in NASH. Preliminary data show also that the
combination of lifestyle changes with drugs (i.e. with TZDs
or statins) may achieve sustained histological remission
even after drug discontinuation (161).
Future adequately powered RCTs with histological end
points, of appropriate duration will clarify long-term safety
and efficacy of proposed treatments.
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